Table 1 CD93, IGFBP7, and MMRN2 expression and clinical parameters in various solid tumors
Human tumor type | molecule | sample | Expression level compared to normal tissue | The relationship between molecule expression and clinical parameters | Ref. |
|---|---|---|---|---|---|
Breast cancer | IGFBP7 | Tumor sample | Not done | Low IGFBP7 expression was related to less recurrence risk. with high IGFBP7 expression, the prognosis was dependent on host factors and treatment | [75] |
IGFBP7 | Tumor sample | Evaluated | Not done | [34] | |
Colorectal cancer | IGFBP7 | Serum sample | Evaluated | No significant differenced | [77] |
IGFBP7 | Tumor sample | Not done | IGFBP7+ was related to a worse prognosis, including early recurrence and shorter survival time compared to IGFBP7- | [78] | |
CD93 | Tumor sample | Elevated | Not done | [80] | |
CD93 | Plasma sample | Reduced | Not done | [80] | |
IGFBP7 | Tumor sample | Reduced | Low IGFBP7 expression promoted metastasis in colon cancer | [79] | |
Cholangiocarcinoma (CCA) | IGFBP7 | Tumor sample | Not done | Patients with IGFBP7 high expression had better overall survival than IGFBP7 low expression. | [47] |
Gastric cancer | IGFBP7 | Tumor sample | Evaluated | Evaluated IGFBP7 expression was related to short survival | [82] |
IGFBP7 | Tumor sample | Not done | IGFBP7 expression upregulation was associated with poor disease-specific survival, advanced stages in tumors with lymph node metastasis, and distant metastasis and recurrence. | [83] | |
IGFBP7 | Tumor sample | Reduced | IGFBP7 expression downregulation was associated with unfavorable clinical outcome | [85] | |
IGFBP7 | Tumor sample | Reduced | IGFBP7 expression downregulation was associated with poor prognosis, including the depth of invasion, lymph node metastasis, and TNM stage. | [84] | |
MMRN2 | Tumor sample | Reduced | Not done | [86] | |
Glioma | MMRN2 | Tumor sample | Evaluated | MMRN2 expression upregulation was associated with shorter OS in low-grade glioma (IGG) | [89] |
IGFBP7 | Tumor sample | Reduced | IGFBP7 expression downregulation was associated with larger tumor size and shorter overall survival. | [87] | |
IGFBP7 | Tumor sample | Evaluated | Not done in glioblastoma | [88] | |
CD93 | Tumor sample | Not done | CD93 expression was related to reduced survival, higher tumor grade in glioblastoma | [7] | |
Hepatocellular carcinoma (HCC) | IGFBP7 | Tumor sample | Reduced | IGFBP7 expression downregulation was associated with advanced tumor stage and grade. | [44] |
IGFBP7 | Tumor sample | Not done | Downregulation was related to poorer prognosis, including shorter disease-free survival (DFS) and overall survival (OS) rate. | [90] | |
Lung cancer | IGFBP7 | Tumor sample | Not done | IGFBP7+ was related to metastasis in non-small cell lung carcinoma | [92] |
IGFBP7 | Serum sample | Not done | IGFBP7 expression was positively related to the clinical stage and lymphatic metastasis in lung adenocarcinoma | [94] | |
Esophagogastric junction adenocarcinoma (EJA) | IGFBP7 | Serum sample | Evaluated | IGFBP7 expression upregulation was associated with longer OS | [81] |
Nasopharyngeal carcinoma (NPC) | CD93 | Tumor sample | Evaluated | CD93 expression upregulation was associated with higher T classification, N classification, distant metastasis, clinical stage, and poor prognosis | [95] |
High-grade serous ovarian carcinoma (HGSC) | IGFBP7 | Tumor sample | Reduced | IGFBP7 expression downregulation was associated with shorter overall survival. | [96] |
Oesophageal adenocarcinoma | IGFBP7 | Tumor sample | Elevated | IGFBP7 expression upregulation was associated with lower median survival and 5-year survival. | [97] |
Oropharyngeal cancer | IGFBP7 | Salivary sample | Elevated | Not done | [98] |
Pancreatic cancer | IGFBP7 | Tumor sample | Reduced | IGFBP7 expression downregulation was associated with poor OS | [99] |
Soft-tissue sarcomas (STS) | IGFBP7 | Tumor sample | Not done | IGFBP7+ was associated with elevated metastatic risk compared to IGFBP7- | [101] |
IGFBP7 | Blood samples | Evaluated | Not done | [101] | |
Thyroid carcinoma | IGFBP7 | Tumor sample | Reduced | Not done | [48] |